• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Battery-free, smart contact lens delivers glaucoma drugs

Article

Investigators from the Sun Yay-Sen University in Guangzhou have created a theranostic device that targets sensing rising fluid pressures within the eye to automatically deliver medication for a glaucoma patient.

Early testing of a smart contact lens shows promise for treating glaucoma, according to researchers in China.

  Investigators from the Sun Yay-Sen University in Guangzhou have created a theranostic device that targets sensing rising fluid pressures within the eye to automatically deliver medication for a glaucoma patient.

Investigators from the Sun Yay-Sen University in Guangzhou have created a theranostic device that targets sensing rising fluid pressures within the eye to automatically deliver medication for a glaucoma patient.

The wireless, double-layer contact lens measures intraocular pressure (IOP) by using small sensors—similar to that of a sandwich—that, when squeezed together, create an electrical signal.

When strong enough, the signal directly triggers the delivery of an anti-glaucoma drug. The drug is stored in a hydrogel layer that is within the lens and is delivered into the cornea with the aid of a weak electrical current.

The wireless, double-layer design of the contact lens creates a device that is minimally invasive, battery-free, and has the potential for large-scale production, as its manufacturing process is compatible with the commercial production of printed circuit boards, according to investigators.

The researchers recently published their findings in Nature Communications, where they reported results from testing the lens on the eyes of pigs and live rabbits.

In the rabbit experiment, the anti-glaucoma drug delivery lowered the IOP by about one-third within 30 minutes. It also helped to maintain those levels for a longer period of time when compared to delivery of the same drug via an eye drop (in which the IOP quickly bounced back).

Additional research is needed before clinical testing of the contact lens device can be done on human patients diagnosed with glaucoma.

According to researchers, the ideal device would consistently respond to fluctuations in an individual’s IOP before it ends up causing irreversible vision loss.

Related Videos
Charles Leclercq, CEO of ARxVision, details the new ARx AI headset and its uses
The Vision Council CEO Ashley Mills gives a preview of the 2024 Vision Expo East event
Eric Fazio, OD, talks EVO ICLs versus LASIK for patients in interview with Optometry Times
R Tracy Williams, OD, FAAO, tells his favorite stories as a team optometrist for the Chicago Bulls, White Sox
Shan Lin, MD, speaks on Glaucoma 360 presentation in an interview with Ophthalmology Times
Danica Marrelli, OD, FAAO, AAO Dipl, co-chair of EnVision Summit chats about geographic atrophy and glaucoma panels
© 2024 MJH Life Sciences

All rights reserved.